New £750K global vaccine collaboration

16 January 2026

iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.

This £750,000 ($1,009 million) international initiative will combine Eyam’s advanced vaccine design and delivery platforms with world-leading automated organoid technology from iiCON’s lead partner, Liverpool School of Tropical Medicine (LSTM), to accelerate the R&D and testing of vaccines against infectious diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical